Back to top
more

UCB (UCBJF)

(Delayed Data from OTC)

$128.73 USD

128.73
745

+2.68 (2.12%)

Updated Apr 19, 2024 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Momentum in UCB SA (UCBJF) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, UCB SA (UCBJF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"

by Zacks Equity Research

UCB SA (UCBJF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate

by Zacks Equity Research

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.

Pharma Stocks Weighed Down by Competition, Generic Pressure

by Zacks Equity Research

Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.

    Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

    by Zacks Equity Research

    Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

      Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

      by Zacks Equity Research

      Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.

        Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

        by Zacks Equity Research

        Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).

          Arpita Dutt headshot

          Key FDA Events to Watch Out for in Jul 2017

          by Arpita Dutt

          Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?

            Adamas Provides Positive Long-term Data on Parkinson's Drug

            by Zacks Equity Research

            Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.

              6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017

              by Zacks Equity Research

              Glaxo carries a Zacks Rank #2 (Buy).

                Amgen Files for Approval of Osteoporosis Drug in Japan

                by Zacks Equity Research

                Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

                  Arpita Dutt headshot

                  Pharma Stock Outlook: Let's Make a Deal

                  by Arpita Dutt

                  M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.

                    Arpita Dutt headshot

                    Pharma Stock Outlook: Let's Make a Deal

                    by Arpita Dutt

                    M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.